# Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

> **NCT02176525** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 75 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** BI 207127 NA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02176525
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176525, "Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT02176525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*